
Advancing Care in Unresectable Stage III NSCLC: Consolidation Immunotherapy and Beyond
Please visit answersincme.com/860/97150451-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prof. Solange Peters, MD, PhD and Kristin Higgins, MD. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss practical steps for integrating consolidation immunotherapy in unresectable stage III NSCLC. Upon completion of this activity, participants should be better able to: Review the implications of the latest evidence evaluating immunotherapy (IO)-based regimens in resectable and unresectable early-stage non-small cell lung cancer (NSCLC); Outline multidisciplinary approaches to optimize perioperative and consolidation IO-based treatment strategies in patients with early-stage NSCLC; and Integrate patient-centered care into the management of early-stage NSCLC.
Information
- Show
- FrequencyUpdated Weekly
- PublishedJanuary 28, 2026 at 11:00 PM UTC
- Length29 min
- RatingClean